Abstract
Benorylate was compared with indomethacin in a double-blind cross-over trial in patients with rheumatoid arthritis. Twelve patients completed treatment. All measurements showed a trend towards benorylate giving greater improvement, although the differences were not statistically significant. Nine patients out of the twelve preferred benorylate.